MYSM1: A Potential Drug Target for Improved Myocardial Infarction Treatment

Target Name: MYSM1

NCBI ID: G114803

MYSM1

MYSM1: A Potential Drug Target for Improved Myocardial Infarction Treatment

Myocardial infarction (heart attack) is a leading cause of morbidity and mortality worldwide, with an estimated 1.7 million deaths in the United States alone in 2020. The treatment of myocardial infarction involves a combination of medications, lifestyle modifications, and surgical interventions. However, despite these efforts, the survival rate for patients with myocardial infarction remains relatively low. Therefore, there is a need for new and better treatments to improve outcomes.

One potential drug target that has been identified is MYSM1 (RP4-592A1.1).MYSM1 is a protein that is expressed in the hearts of many organisms, including humans. It is involved in a variety of cellular processes that are important for heart function, including contractility, inflammation, and fibrosis.

MYSM1 has been shown to be involved in several processes that are central to the development and progression of myocardial infarction. For example, studies have shown that MYSM1 is involved in the recruitment of immune cells to the site of the infarction, which can contribute to inflammation and tissue damage. Additionally, MYSM1 has been shown to play a role in the regulation of ion channels, which are critical for the electrical activity of the heart.

Despite these promising findings, more research is needed to fully understand the role of MYSM1 in myocardial infarction. One reason for this is that there are few validated biomarkers that can be used to predict the outcome of myocardial infarction. This makes it difficult to determine the effectiveness of new treatments or to compare different approaches.

MYSM1 may be a valuable drug target because it is involved in several processes that are important for heart function. Additionally, because it is expressed in many different organisms, it may be possible to use it as a biomarker to predict the outcome of myocardial infarction. Further research is needed to fully understand the role of MYSM1 in myocardial infarction and to develop new treatments.

Protein Name: Myb Like, SWIRM And MPN Domains 1

Functions: Metalloprotease with deubiquitinase activity that plays important regulator roles in hematopoietic stem cell function, blood cell production and immune response (PubMed:24062447, PubMed:26220525, PubMed:28115216). Participates in the normal programming of B-cell responses to antigen after the maturation process (By similarity). Within the cytoplasm, plays critical roles in the repression of innate immunity and autoimmunity (PubMed:33086059). Removes 'Lys-63'-linked polyubiquitins from TRAF3 and TRAF6 complexes (By similarity). Attenuates NOD2-mediated inflammation and tissue injury by promoting 'Lys-63'-linked deubiquitination of RIPK2 component (By similarity). Suppresses the CGAS-STING1 signaling pathway by cleaving STING1 'Lys-63'-linked ubiquitin chains (PubMed:33086059). In the nucleus, acts as a hematopoietic transcription regulator derepressing a range of genes essential for normal stem cell differentiation including EBF1 and PAX5 in B-cells, ID2 in NK-cell progenitor or FLT3 in dendritic cell precursors (PubMed:24062447). Deubiquitinates monoubiquitinated histone H2A, a specific tag for epigenetic transcriptional repression, leading to dissociation of histone H1 from the nucleosome (PubMed:17707232)

The "MYSM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYSM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets